

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT AND BUSINESS DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Group has obtained the approvals for drug production and registration for Felodipine Sustained-release Tablets (5mg) and Lacosamide Injection (20ml:0.2g) from the National Medical Products Administration of China, both being under type 4 chemical drug and regarded as passing the consistency evaluation. Felodipine Sustained-release Tablets are mainly used in treatment of high blood pressure and stable angina, and Lacosamide Injection is mainly used in combination therapy for partial-onset seizures in epilepsy patients.

In addition, the Board is also pleased to announce that, according to the List of Quality Benchmark for Industrial Enterprises of Hebei Province in 2022 (2022年河北省工業企業質量標桿名單) announced by the Department of Industry and Information Technology of Hebei Province, the “Experience in comprehensive quality control methods based on green manufacturing of bulk pharmaceuticals” of Hebei Guolong Pharmaceutical Co., Ltd., a wholly-owned subsidiary in the Group, was recognised as the quality benchmark for industrial enterprises of Hebei Province in 2022. Enterprises which had such quality benchmark will continue to apply advanced quality control methods to promote steady improvements in quality and efficiency of their products and services.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 5 January 2023

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.